Boone v. Boehringer Ingelheim Pharmaceuticals, Inc.

Summary

The court affirmed the judgment for the defendants after rejecting four appellate challenges concerning spoliation evidence, rebuttal testimony, federal preemption, and a curative jury instruction. It held that the plaintiff invited the restrictions on spoliation evidence, that the excluded deposition excerpt was not proper rebuttal, that the reversal-agent design-defect claim was preempted because federal approval was required, and that the curative instruction did not constitute reversible error.